Literature DB >> 3149492

Hepatitis B virus reactivation or reinfection associated with HIV-1 infection.

J Waite1, R J Gilson, I V Weller, C J Lacey, M H Hambling, A Hawkins, M Briggs, R S Tedder.   

Abstract

Following acute hepatitis B virus (HBV) infection, most individuals develop antibodies to HBV surface (anti-HBs) and core antigen (anti-HBc). Prevalence studies have shown that 10-18% develop anti-HBc in the absence of detectable anti-HBs. We report four such cases, all with persistence of serum anti-HBc, who had evidence of a second period of active HBV replication as demonstrated by the reappearance of serum hepatitis B surface antigen (HBsAg). In one patient, an HBsAg subtype difference indicated that the second period of HBsAg-positivity was due to a reinfection. In the other cases, reactivation may also explain the findings. All cases were anti-HIV-1 seropositive at the time of reappearance of HBsAg. There is experimental evidence that anti-HBc has a protective effect against HBV infection; however, this may require intact cell-mediated immunity to be effective. HIV-1 infection may render such patients susceptible to reinfection. Alternatively, some patients with anti-HBc, but without detectable anti-HBs may have latent HBV infection. Immunosuppression associated with HIV-1 infection may allow reactivation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149492     DOI: 10.1097/00002030-198812000-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

2.  Hepatitis B reactivation after chemotherapy: two decades of clinical research.

Authors:  George K K Lau
Journal:  Hepatol Int       Date:  2008-03-05       Impact factor: 6.047

3.  Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India.

Authors:  Swati Gupta; Sarman Singh
Journal:  BMC Infect Dis       Date:  2010-03-07       Impact factor: 3.090

4.  Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection.

Authors:  T Wölfel; P Schirmacher; J Schlaak; P Knolle; H P Dienes; W Dippold; K H Meyer zum Büschenfelde; G Gerken
Journal:  Clin Investig       Date:  1994-12

5.  Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Authors:  Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-01       Impact factor: 11.382

6.  Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey.

Authors:  Josephine Bwogi; Fiona Braka; Issa Makumbi; Vinod Mishra; Barnabas Bakamutumaho; Miriam Nanyunja; Alex Opio; Robert Downing; Benon Biryahwaho; Rosamund F Lewis
Journal:  Afr Health Sci       Date:  2009-06       Impact factor: 0.927

Review 7.  Therapeutic potential of ectopic olfactory and taste receptors.

Authors:  Sung-Joon Lee; Inge Depoortere; Hanns Hatt
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

8.  HBsAg may reappear following reactivation in individuals with spontaneous HBsAg seroclearance 8 years previously.

Authors:  Q Y Chen; X Y Wang; T J Harrison; X He; L P Hu; K W Li; H H Jia; Q L Yang; C Wang; Z L Fang
Journal:  Epidemiol Infect       Date:  2016-12-05       Impact factor: 4.434

9.  Hepatitis B virus infection in a cohort of HIV infected blood donors and AIDS patients in Sichuan, China.

Authors:  Yu Liu; Peibin Zeng; Jingxing Wang; Gui Liu; Min Xu; Ling Ke; Miao He; Zhong Liu
Journal:  J Transl Med       Date:  2014-06-12       Impact factor: 5.531

10.  Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody.

Authors:  Nattinee Laksananun; Jutarat Praparattanapan; Wilai Kotarathititum; Khuanchai Supparatpinyo; Romanee Chaiwarith
Journal:  AIDS Res Ther       Date:  2019-05-03       Impact factor: 2.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.